Stocks · News reference
AlphaValue/Baader Europe Downgrades Genmab to Reduce
AlphaValue/Baader Europe has downgraded its rating for Genmab A/S to "Reduce" on October 28, 2026.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Genmab Announces Positive Phase 3 Results for Petosemtamab Combination
Genmab reported that its Phase 3 LiGeR-HN1 trial of petosemtamab in combination with pembrolizumab met both primary endpoints in patients with first-line PD-L1 positive recurrent/metastatic head and neck squamous cell carcinoma.
TD Cowen Maintains Buy on Genmab, Raises Price Target to $52